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Abstract
Significance: Hepatic fibrosis is the common pathophysiologic process resulting from chronic liver injury,
characterized by the accumulation of an excessive extracellular matrix. Multiple lines of evidence indicate that
oxidative stress plays a pivotal role in the pathogenesis of liver fibrosis. Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX) is a multicomponent enzyme complex that generates reactive oxygen
species (ROS) in response to a wide range of stimuli. In addition to phagocytic NOX2, there are six non-
phagocytic NOX proteins. Recent Advances: In the liver, NOX is functionally expressed both in the phagocytic
form and in the nonphagocytic form. NOX-derived ROS contributes to various kinds of liver disease caused by
alcohol, hepatitis C virus, and toxic bile acids. Recent evidence indicates that both phagocytic NOX2 and
nonphagocytic NOX isoforms, including NOX1 and NOX4, mediate distinct profibrogenic actions in hepatic
stellate cells, the main fibrogenic cell type in the liver. The critical role of NOX in hepatic fibrogenesis provides a
rationale to assess pharmacological NOX inhibitors that treat hepatic fibrosis in patients with chronic liver
disease. Critical Issues: Although there is compelling evidence indicating a crucial role for NOX-mediated ROS
generation in hepatic fibrogenesis, little is known about the expression, subcellular localization, regulation, and
redox signaling of NOX isoforms in specific cell types in the liver. Moreover, the exact mechanism of NOX-
mediated fibrogenic signaling is still largely unknown. Future Directions: A better understanding through
further research about NOX-mediated fibrogenic signaling may enable the development of novel anti-fibrotic
therapy using NOX inhibition strategy. Antioxid. Redox Signal. 20, 2854–2872.
Introduction
Liver fibrosis is the accumulation of extracellular matrix(ECM) proteins, mainly type I collagen, which occurs in
most types of chronic liver disease. The main causes of liver
fibrosis in industrialized countries include chronic hepatitis C
virus (HCV) or hepatitis B virus (HBV) infection, alcohol
abuse, and nonalcoholic steatohepatitis (NASH) (14). The
accumulation of ECM proteins distorts the hepatic architec-
ture by forming a fibrous scar, and the subsequent develop-
ment of nodules of regenerating hepatocytes defines cirrhosis
(70). Major complications of cirrhosis are portal hypertension
and liver failure. Portal hypertension can lead to serious
complications such as variceal bleeding, ascites, spontaneous
bacterial peritonitis, and hepatic encephalopathy that are the
major causes of mortality in cirrhotic patients. Cirrhosis also
leads to the development of hepatocellular carcinoma (HCC)
(204).
Liver fibrosis is a model of the wound-healing response to
chronic liver injury. Hepatic stellate cells (HSCs), formerly
known as lipocytes, Ito cells, or perisinusoidal cells, have been
identified as the main collagen-producing cells in the liver
(72). This cell type undergoes a dramatic phenotypic change
in chronic liver diseases with the acquisition of fibrogenic
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properties. Quiescent HSCs are desmin-positive, perisinusoi-
dal cells that are the primary cells in the body which are re-
sponsible for vitamin A storage (14). On activation by liver
injury, quiescent HSCs transdifferentiate into myofibroblasts
that produce inflammatory cytokines and several ECM pro-
teins, including at least five collagen types, fibronectin, un-
dulin, elastin, laminin, entactin, tenascin, and several
proteoglycans (71). The molecular mechanisms leading to
HSCs activation and increased ECM synthesis in liver fibrosis
have been extensively investigated by using cultured HSCs and
experimental models of chronic liver injury in rodents (14, 70,
153, 161). Besides HSCs, portal fibroblasts and cells of bone
marrow origin have fibrogenic potential (106, 155, 167). Recent
knowledge indicates that most fibrogenic myofibroblasts are
endogenous to the liver, and activated HSCs and fibroblasts are
the major endogenous fibrogenic cells in the liver (26).
The demonstration that even advanced liver fibrosis may
be reversible has stimulated researchers to investigate anti-
fibrotic therapies (83, 111). The only effective, available ther-
apy to treat hepatic fibrosis to date is to remove the causative
agent (13). For example, long-term administration of oral
nucleos(t)ide analogues demonstrate the regression of liver
fibrosis in patients with advanced liver fibrosis or even cir-
rhosis caused by chronic HBV infection (38, 126). Similarly,
peginterferon a significantly reduces hepatic fibrosis in pa-
tients with chronic hepatitis C with or without cirrhosis in
whom sustained virologic response occurs (32). However, a
number of drugs are able to reduce liver fibrosis in experi-
mental models without affecting the etiological agent causing
the injury. Several candidate drugs, including antioxidants
and renin-angiotensin system (RAS) blockers, have been
evaluated for their anti-fibrotic efficacy and safety; however,
evidence-based therapies are not yet available (17).
Reactive oxygen species (ROS) are involved as key
secondary messengers in numerous signaling pathways,
including transcriptional regulation, differentiation, prolifer-
ation, oncogenic transformation, and activation of pro-
grammed cell death (28). ROS contributes to the hepatic
fibrosis from various kinds of liver injuries, including alcohol
abuse, HCV infection, iron overload, and chronic cholestasis
(150, 154). ROS can stimulate the production of the type I
collagen, and may act as an intracellular signaling mediator of
the fibrogenic action of TGF-b (56, 124, 136). ROS may be
generated in the liver by multiple sources, including the mi-
tochondrial respiratory chain, cytochrome P450 (CYP) family
members, peroxisomes, xanthine oxidase, and nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases (55, 150).
Accumulating evidence indicates that NADPH oxidases
(NOXs)-mediated ROS has a critical role in HSCs activation
and hepatic fibrogenesis. This review summarizes the current
knowledge on the profibrogenic mechanisms of various NOX
isoforms expressed in specific cell types in the liver, with
particular focus on HSCs and discusses NOX isoforms as
potential therapeutic targets for hepatic fibrosis.
NADPH Oxidases
NOX is a multimeric transmembrane enzyme complex that
generates superoxide (O2
 - ) and hydrogen peroxide (H2O2)
from molecular oxygen using NADPH as an electron donor
(21). The mammalian NOX family comprises seven isoforms:
NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2
(Table 1) (21, 113). Classic NOX is the phagocytic NOX found
in neutrophils. The phagocytic NOX contains a heterodymeric
membrane-bound flavocytochrome b558 complex, which
consists of the catalytic subunit gp91phox (renamed NOX2)
and the regulatory subunit p22phox located in the membrane
(21, 162). Rac is a component required for the activation of
NOX2. Rac is a member of the Rho family of small GTPase
proteins that regulates cell proliferation and dynamic reorga-
nization of the actin cytoskeleton (44). The NOX2 regulatory
components, p47phox, p40phox, p67phox, and Rac, are usually
located in the cytoplasm (21). On stimulation with agonists, the
cytosolic subunits translocate to the membrane-bound flavo-
cytochrome complex, leading to enzymatic activity.
NOX2-derived ROS acts in immune defense in neutrophils
and phagocytes (21). The genetic defect of phagocytic NOX
(NOX2) activity called chronic granulomatous disease (CGD)
results in an inability to produce the superoxide anion that is
necessary for killing bacteria and fungi by neutrophils and
Table 1. The Characteristics of Selected NOX Isoforms
Catalytic




Colon, vessel, heart, uterus,
prostate, liver
















Fetal tissue, inner ear Plasma membrane
NOX4 NOX4, p22phox, POLDIP2 Kidney, vessel, heart, lung,
liver
TGF-b, TNF-a, IFN-c Endoplasmic reticulum,
focal adhesion
NOX5 NOX5 Testis, spleen, lymph node,
heart, vessel




Ang II, angiotensin II; EGF, epidermal growth factor; NOX, NADPH oxidase; IFN, interferon.
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phagocytes. Patients with CGD are predisposed to serious
bacterial and fungal infections as well as granulomatous
complications (170). In contrast with CGD that are defective in
NOX-mediated ROS generation, hereditary amyotrophic lat-
eral sclerosis (ALS), a progressive motor neuron degenerative
disease, may result from excessive ROS production by an
overactive NOX (36).
Compared with NOX2 that is expressed in phagocytes,
the nonphagocytic NOXs are expressed at low levels in
complex tissue compartments composed of multiple cell types
and different NOX isoforms (135). Among the seven isoforms
of the NOX family, NOX1, NOX2, NOX3, and NOX4 form
heterodimers with p22phox, whereas NOX5, DUOX1, and
DUOX2 function without an association with p22phox. In-
stead, NOX5, DUOX1, and DUOX2 contain EF-hand calcium-
binding motif (135). While NOX1 is also p22phox dependent,
NOX1 may use NOXO1 (homologue of p47phox, an organizing
cofactor) to organize the enzyme assembly and NOXA1 (ho-
mologue of p67phox, an activating cofactor) for enzyme acti-
vation (12). In many cases, neither NOXO1 nor NOXA1 has
been identified in tissues where the implicated NOX protein
will require these co-factors for activity (135). In contrast to
other NOX isoforms, NOX4 requires only p22phox without
recruitment of cytosolic regulatory components to exert its
enzymatic activity (21, 76). All NOX enzymes are able to
catalyze the reduction of molecular oxygen to superoxide, but
there are key differences in their expression, subcellular lo-
calization, activation, and intracellular signaling.
Cellular distribution of NOXs in the liver
In the liver, NOX is functionally expressed both in the
phagocytic form and in the nonphagocytic form (18, 192).
Various NOX isoforms such as NOX1, NOX2, and NOX4 are
distinctively expressed in the specific cell types, including
Kupffer cells (KCs), HSCs, endothelial cells (ECs), hepato-
cytes, and infiltrating leukocytes in the liver (Fig. 1) (59, 143).
KCs, the resident macrophage in the liver, express phagocytic
NOX2 and its regulatory components such as p40phox,
p47phox, and p67phox. There is no detectable mRNA expression
for other NOX forms such as NOX1, NOX4 in KCs (143). In
HSCs, both phagocytic NOX2 and nonphagocytic NOXs such
as NOX1 and NOX4 are expressed (143). In ECs, NOX1,
NOX2, and NOX4 are expressed (99, 134, 143). NOXO1 and
NOXA1 are predominant regulatory components expressed
in ECs and HSCs (143). Hepatocytes express mRNAs for
NOX1, NOX2, NOX4, DUOX1, and DUOX2 as well as regu-
latory subunit p47phox (35, 60, 143, 157).
Subcellular localization of NOX characterizes
signal transduction
NOX-generated superoxide anion has a short half life and
is rapidly dismutated to H2O2 at a rate constant of 8 · 104
M - 1s - 1 spontaneously and 2 · 109 M - 1s - 1 by superoxide
dismutase (SOD) (69). H2O2 is more stable than superoxide
and is able to cross the cell membrane. ROS can react with
nearby cellular proteins reversibly (40, 193). These properties
of diffusibility, short half life, and reversible reactivity make
ROS function as signal messengers. Complexity of NOX sig-
naling arises from the multiple NOX isoforms that are ex-
pressed within the same cell and mediate distinctive signaling
pathways in response to diverse stimuli. The specific subcel-
lular localization of NOX isoforms and their regulatory sub-
units within specific subcellular compartments may modulate
the specificity of ROS-mediated signal transduction (152, 186).
NOX2 is predominantly expressed in the plasma mem-
brane. Stimulation of ECs with Fas ligand or TNF-a induces
translocation of NOX2, p47phox, and Rac1 to the lamellipodial
leading edge of the cell, where the focal complexes undergo
rapid turnover and ROS production promotes cytoskeleton
rearrangement for directional cell migration (94, 133, 194,
196). NOX2 also targets to phagosomes in neutrophils and to
endosomes in nonphagocytic cells, dubbed as ‘‘redoxosomes’’
(119, 138, 139). Redoxosomal NOX2 transduces several stim-
uli, such as angiopoietin-1, vascular endothelial growth fac-
tor, thrombin, and TNF-a, into necrosis and angiogenesis via
ROS production (63, 125, 187). p22phox is essential for optimal
FIG. 1. Cellular distribution of NOX isoforms in the liver. Various kinds of cell types in the liver, including hepatocytes,
KCs, ECs, HSCs, and infiltrating leukocytes express multiple NOX isoforms, including both phagocytic and nonphagocytic
NOX. ECs, endothelial cells; HSCs, hepatic stellate cells; KCs, Kupffer cells; NOX, NADPH oxidase. To see this illustration in
color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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activity of NOX2. In myeloid cells, coexpression and hetero-
dimerization of NOX2 and p22phox are required for the mi-
gration from the endoplasmic reticulum (ER) and proper
localization in the plasma membrane (61). A mouse model of
hepatic fibrosis shows that NOX2 level is elevated in activated
HSCs (98, 143). However, the subcellular localization of
NOX2 in HSCs has not been identified.
NOX1 has been found at the plasma membrane, in early
endosomes, and in the nucleus in vascular smooth muscle
cells (VSMCs) (92, 131). Recently, it was reported that NOX1 is
also found in caveolin 1-containing lipid rafts in VSMCs (92,
186, 206). Binding of angiotensin II (Ang II) stimulates the
angiotensin type I receptor (AT1R) to translocate to caveola,
where Rac1 is also recruited to locally produce ROS with
subsequent activation of epidermal growth factor receptor
(EGFR). NOX1 is also involved in endosomal ROS production
after hypoxia-reoxygenation injury, which requires both Rac-1
and c-Src recruitment (120). In addition, chloride channel 3 is
co-localized for TNF-a-induced NOX1-mediated ROS pro-
duction, leading to NF-jB activation, at early endosomes in
vascular cells (131). In Huh7 cells, a human hepatoma cell line,
NOX1 predominantly localizes in the cytoplasm, with ap-
parent punctuate staining at the plasma membrane, even
though the identity of these punctuate stains was not specif-
ically addressed (60). Although NOX1 is expressed in HSCs,
ECs, and hepatocytes in the liver (143, 157), its subcellular
localization in these cells has not yet been investigated.
NOX4 is ubiquitously expressed and inducible (27). Unlike
other NOX, NOX4 does not require regulatory cellular bind-
ing partners and is constitutively active. However, p22phox is
required for the enzymatic activity (5, 21, 39, 123). NOX4 is not
only mainly localized in the perinuclear, ER area, but it is also
detected at the plasma membrane, at focal adhesions, and
within the nucleus (21). NOX4 is localized to the ER in VSMCs
and ECs (41, 89, 195), at both ER and nucleus in renal cortical
cells (151, 164), in the nucleus in monocytes and ECs, at the
plasma membrane of lung epithelial cells (188, 189), and only
in mitochondria in breast tumors and adipose-derived stem
cells (78, 103). There are several possibilities for these con-
flicting reports for NOX4 localization. Different cell types with
various functions might require local ROS production at
various subcellular locations. It is also possible that NOX4
localization might be transient; different stimulation might
lead NOX4 to translocate from one place to others for the
necessary local ROS. Indeed, HCV infection in a hepatocyte
cell line increases NOX4 expression level and also increases
nuclear localization (60). In experiments with primary
VSMCs, NOX4 relocates from actin-based stress fibers to focal
adhesions on de-differentiation (47). NOX4 has several splic-
ing variants, which might determine localization: In the A549
lung cell line, some splicing variants are detected in the ER
and others are detected at the plasma membrane (77). Alter-
natively, different antibodies might recognize different iso-
forms of the NOX4. For example, two antibodies discovered
through phage-display screening share similar epitopes and
neutralize NOX4 enzymatic activity, but only one antibody
detects NOX4 at the plasma membrane (205).
Role of NOX-Derived ROS in Liver Diseases
Oxidative stress contributes to a variety of liver diseases,
including alcohol abuse, acetaminophen, HCV, iron overload,
chronic cholestasis, and ischemia-reperfusion (55). Small
amounts of ROS are usually released by the mitochondrial
respiratory chain in the liver. Liver injury can develop when
excessive amounts of ROS are generated from multiple po-
tential sources, including the mitochondrial respiratory chain,
CYP family members, peroxisomes, xanthine oxidase, and
NOX (55, 150). It has been reported that NOX-mediated ROS
contributes to various liver diseases, including alcoholic
hepatitis (107, 109), chronic hepatitis C (24, 29, 60, 183), cho-
lestatic liver injury (157, 158, 177, 180), and hepatic fibrosis
(16, 18, 58, 59, 98, 143).
The phagocytic NOX2 releases large amounts of superox-
ide anion in bursts in response to agonists, exhibiting no de-
tectable constitutive activity. While the nonphagocytic NOX
produce low levels of superoxide intracellularly in the basal
state, which can be further stimulated by various agonists (68).
NOX generates ROS in response to a wide range of stimuli,
including TNF-a, IL-1b, Ang II, and leptin (42, 57). All NOX
isoforms generate superoxide from molecular oxygen, and
superoxide is converted to H2O2 by SOD. However, the kind of
ROS may vary according to specific NOX isoforms that are
expressed in specific cells. For example, NOX4 generates pre-
dominantly H2O2 instead of superoxide (128, 173). ROS de-
rived from specific NOX isoforms in specific cell types in the
liver may serve as diverse signaling function by inducing
specific biochemical changes in their molecular targets.
Alcoholic hepatitis
There is strong evidence that ROS play a pivotal role in
alcohol-induced liver injury. Ethanol-induced oxidative stress
results in a hepatocellular injury by promoting hepatocyte
apoptosis or necrosis and also contributes to hepatic fibrosis
by triggering the release of profibrogenic cytokines and HSCs
activation (3). Ethanol induces ROS production by several
enzymatic systems, including the CYP2E microsomal mono-
oxygenase system, mitochondrial respiratory chain, and NOX
(9). Both intracellular and extracellular sources of ROS con-
tribute to alcohol-induced oxidative stress (3). Oxidative DNA
damage as an index of intracellular oxidative stress is de-
creased in CYP2E1-deficient mice but not in p47phox-deficient
mice (25). However, CYP2E1-deficient mice are not protected
from early alcohol-induced liver injury (107). Four-week in-
tragastric alcohol administration to p47phox-deficient mice re-
sults in less hepatic-free radical production and liver pathology
compared with wild-type (WT) mice (109). KCs highly express
phagocytic NOX2 and generate ROS during early ethanol-
induced liver injury (192). Collectively, these data indicate that
ROS from NOX in hepatic KCs plays a critical role in the
pathogenesis of early alcohol-induced hepatitis.
The important role of NOX in the pathogenesis of alcoholic
liver disease is corroborated by microarray analysis of hepatic
gene expression in patients with alcoholic hepatitis (48). As
expected, the expression of genes encoding ECMs such as
procollagen a1(I), a4(I), fibrogenesis mediators, and inflam-
matory cytokines are markedly elevated in human livers with
alcoholic hepatitis. In addition, various NOX components,
including DUOX2 (23-fold), NOX4 (12.7-fold), DUOX1 (6.7-
fold), p22phox (2.0-fold), and Rac1 (4.1-fold), are upregulated
in the livers with alcoholic hepatitis compared with normal
livers (48). An important finding to note is that nonphagocytic
NOX components (NOX4, DUOX1, and DUOX2) are barely
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detected in normal livers but are de novo expressed in alcoholic
hepatitis (48). Expression of NOX2, NOXO1, NOXA1 are un-
changed and other NOX isoforms such as NOX1, NOX3, and
NOX5 are undetected. By contrast, another important ROS
generator CYP2E1 is down-regulated in the livers with alco-
holic hepatitis (48). Taken together, these results suggest that
nonphagocytic NOX isoforms such as NOX4 and DUOXs as
well as phagocytic NOX2 mediate alcohol-induced liver injury.
HCV-induced hepatocellular damage
HCV is the leading cause of mortality from chronic liver
disease, including cirrhosis and HCC in many countries in-
cluding Japan, Southern Europe, and the United States (66).
Accumulating evidence suggests that ROS play an important
role in the development and progression of chronic hepatitis
C (43). HCV is a 9.6-kb positive strand RNA virus consisting
of 10 genes that encode 4 structural and 6 nonstructural pro-
teins (24). Among 10 HCV proteins, the core, NS3, and NS5a
protein are associated with increased oxidative stress (16, 29,
74, 141). Recombinant NS3 protein phosphorylates p47phox
and activates NOX to produce ROS, mainly superoxide, in
human monocytes (29). A strong HCV-specific T-cell re-
sponse, especially CD4 + T-cell response, is critical for the
clearance of HCV in patients with acute HCV infection (101,
182). NS3 protein induces a prolonged release of ROS via
NOX2 in mononuclear and polymorphonuclear phagocytes,
which, in turn, induces dysfunction and/or apoptosis of
lymphocytes of relevance (183).
Expression of HCV proteins in hepatocytes results in in-
creased ROS generation, steatosis, and cell transformation
developing liver cancer (118, 141). HCV NS5A and core pro-
tein induce ROS and reactive nitrogen species in a human
hepatocyte-derived cell line (74). Expression of HCV (geno-
type Ia) cDNA constructs, core protein, viral RNA, or repli-
cating HCV ( JFH-AM2) induces NOX4 mRNA expression
and ROS production in human hepatocytes cell lines (24).
Dominant-negative NOX4 or knockdown of NOX4 using
NOX4 short hairpin RNA decreases HCV-induced superox-
ide production in a human hepatocyte cell line. Full-length
HCV as well as structural and nonstructural HCV constructs
increases ROS generation in an NOX4-dependent manner.
Human NOX4 promoter/reporter assay demonstrates that
HCV positively regulates both human and murine NOX4 at
the transcriptional level (24). TGF-b1 is a major fibrogenic
cytokine that activates HSCs. TGF-b induces NOX4 in various
cell types, including HSCs, hepatocytes, cardiac fibroblasts,
and VSMCs (35, 53, 97, 163, 179). HCV core protein up-
regulates TGF-b mRNA in HepG2 cells, and treatment of
cells with TGF-b blocking antibody prevents the HCV core-
mediated induction of NOX4 and reduces superoxide pro-
duction (24). Taken together, these data indicate that HCV
induces NOX4-mediated ROS generation via an autocrine
TGF-b dependent mechanism (24).
Huh7 cells transfected with virus producing JFH1 HCV
RNA induces extracellular H2O2 secretion and intracellular
superoxide production (60). Both genotype 2a and Ib HCV
induce NOX1 and its regulators such as NOXO1 and NOXA1
as well as NOX4 in the Huh7 human hepatocyte cell line (60).
Furthermore, the increased expression of NOX1 and NOX4
proteins is demonstrated in HCV-infected human liver (60).
Knockdown of either NOX1 or NOX4 using siRNA signifi-
cantly decreases H2O2 and intracellular superoxide produc-
tion in a hepatocyte cell line producing JFH1 HCV RNA (60).
Interestingly, subcellular localization of NOX1 and NOX4
varies. NOX1 is predominantly located in the cytoplasm, and
this location does not change significantly with HCV ex-
pression in Huh7 cells. While NOX4 is localized in the cyto-
plasm as well as in the nucleus in control Huh7 cells, HCV
increases localization of NOX4 in the ER and nuclear mem-
brane (60). Further investigation is required to understand the
distinct contributory roles of NOX1 and NOX4 in HCV-
induced hepatocyte injury that may result from different
compartmentalization and signaling.
HCV core and NS3 proteins induce a marked increase in
ROS production in human HSCs (16). These effects are
attenuated by the nonspecific NOX inhibitor diphenylene
iodonium (DPI). HCV core protein increases HSC prolifera-
tion in an Ras/extracellular signal-regulated kinase (ERK)
and PI3K/protein kinase B (Akt)-dependent manner. In con-
trast, HCV NS3-NS5 protein preferentially induces proin-
flammatory actions such as chemokine secretion and
expression of cell adhesion molecules through NF-jB and
c-Jun-N-terminal kinase ( JNK) pathways. Both HCV core and
NS3–NS5 proteins increase TGF-b1 secretion and type I col-
lagen expression in HSCs (16). Therefore, HCV induces liver
inflammation and fibrosis, at least in part, via NOX-generated
ROS. The NOX isoforms that are involved in HCV-induced
fibrogenic responses in HSCs are not yet identified.
Hydrophobic bile salts-induced liver injury
Hydrophobic bile salts can induce hepatocytes apoptosis
through a ligand-independent activation of the CD95 death
receptor (132, 176). Taurolithocholate-3-sulfate, a hydropho-
bic proapoptotic bile salt, stimulates ceramide formation
through chloride-dependent acidification of endosomes, with
subsequent activation of acidic sphingomyelinase, which, in
turn, activates protein kinase C (PKC)f (19). Activated PKCf
rapidly induces serine phosphorylation of p47phox, which is
followed by ROS generation in hepatocytes (158). NOX-
derived ROS activates JNK and an Src family kinase Yes,
which then associates with and activates EGFR, followed by
EGFR-catalyzed CD95 tyrosine phosphorylation, formation
of the death-inducing signaling complex, and apoptosis of
hepatocytes (157, 158).
Bile acids also activate EGFR in activated HSCs. In contrast
to hepatocytes, bile acid-induced EGFR activation in HSCs
does not induce apoptosis, but leads to cell proliferation (180).
Hydrophobic bile acids induce phosphorylation of p47phox
and ROS generation followed by a Yes-mediated EGFR acti-
vation, which subsequently phosphorylates ERK1/2 but not
JNK and stimulates cell proliferation in quiescent HSCs (177).
Treatment of cycloheximide or H2O2 in addition to hydro-
phobic bile acid was required for the activation of JNK signal
and for the shift from proliferation to apoptosis in HSCs (177).
NOX-Derived ROS Play a Key Role
in Hepatic Fibrogenesis
Liver fibrosis is a common pathway resulting from chronic
liver injury. Although the pathogenesis of liver fibrosis varies
according to etiology of the injury, oxidative stress seems to
play a crucial role in most types of hepatic fibrogenesis (14).
ROS has diverse effects with regard to different kinds,
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concentrations, and cell types. ROS tend to be compartmen-
talized in the cell and form a concentration gradient that
originates from their sites of generation (20). H2O2 can diffuse
across plasma membrane and throughout the cell; however,
superoxide diffuses poorly across cell membranes (30). High
concentrations of ROS can be cytotoxic, whereas low con-
centrations of ROS may serve as second messengers during
cellular responses to a variety of physiologic stimuli. A low
concentration of H2O2 has mitogenic effects and can mimic
the function of growth factors (159). Regarding the effects of
ROS on HSCs, contradictory results have been reported: both
mitogenic and cell-death inducing properties. Nontoxic levels
of ROS or lipid peroxidation products stimulate the activa-
tion, proliferation, and collagen production of HSCs, but high
concentrations of ROS induce HSCs death (117, 136, 137).
Expression of various NOX isoforms is increased in pa-
tients with heart (91), lung (4), kidney (64), and liver fibrosis
(48, 60). Moreover, NOX-mediated ROS is required for ex-
perimental animal models of fibrosis in various organs, in-
cluding heart (53), lung (87), kidney (169), and liver (143). In
HSCs, NOX mediates the fibrogenic responses in response to
various agonists, including Ang II (18), PDGF (2), leptin (58),
TGF-b (97), phagocytosis of apoptotic body (203), and ad-
vanced glycation end products (81). Taken together, NOX-
derived ROS is a key mediator in hepatic fibrogenesis as well
as in other organs such as the heart, lung, and kidney.
Upregulation of NOX components in activated HSCs
HSCs, the major fibrogenic cell type in the liver, express
multiple NOX isoforms and their regulatory components.
Analysis of mRNA expression of NOX components in isolated
liver cell fractions from WT C57BL/6 mice demonstrated that
WT HSCs express the mRNAs for both phagocytic NOX2 and
nonphagocytic NOX, including NOX1 and NOX4. HSCs also
express other NOX regulatory components, including
p22phox, p40phox, p47phox, p67phox, NOXO1, NOXA1, and
Rac1 (143). These NOX components increase when quiescent
HSCs activate into myofibroblasts. After bile duct ligation
(BDL)-induced fibrosis, the mRNA expression of p47phox is
strongly upregulated in HSCs to a similar degree as in KCs,
whereas less upregulation occurs in other cell types such as
ECs, hepatocytes in the liver (59). The mRNAs for both
phagocytic and nonphagocytic NOX catalytic subunits, in-
cluding NOX1, NOX2, and NOX4, are upregulated in acti-
vated HSCs compared with quiescent HSCs (7, 143).
In human quiescent HSCs, the mRNA for the cytosolic
regulatory factor p47phox and the catalytic subunits NOX2 and
NOX1 at cell membrane are detected at low levels, while they
are highly upregulated in culture-activated HSCs and in vivo-
activated HSCs isolated from patients with liver fibrosis (18).
Although NOX plays an important role in HSCs activation,
the exact structure of this complex is still unknown. All
components and functionalities of the phagocytic NOX are
already well established, but the interactions between the
nonphagocytic NOX components in HSCs are unknown.
Contribution of various NOX isoforms
in hepatic fibrogenesis
Expression of both NOX2 and NOX1 proteins is increased
in the fibrotic liver in mice (143). BDL-induced liver fibrosis is
attenuated in p47phox-deficient mice compared with WT mice
(18). Although the degree of protection was less, metabolically
induced hepatic fibrosis by the methionine choline-deficient
diet is also reduced in p47phox-deficient mice (59). Direct evi-
dence of the contribution of NOX2 in hepatic fibrogenesis is
demonstrated by the attenuated hepatic fibrosis in NOX2-
deficient mice compared with WT mice after CCl4 treatment
or BDL (8, 98). BDL-induced hepatic fibrosis is attenuated in
NOX2-deficient mice regardless of eradication of NOX2 ex-
pressing KCs by GdCl3, demonstrating that NOX2 activity in
HSCs contributes to hepatic fibrosis (98). Furthermore, NOX2
is involved in the activation of HSCs by phagocytosis of ap-
optotic hepatocytes (33, 203). Phagocytosis of apoptotic he-
patocytes induces HSC activation and collagen production via
NOX2, and NOX2-derived ROS induces collagen a1 promoter
activity in HSCs (98). In addition, impaired translocation of
Rac1 to the cell membrane is observed in NOX2-deficient
HSCs (98). Collectively, these data indicate that phagocytic
NOX2 is an important mediator of HSCs activation and he-
patic fibrosis.
It is important to note that nonphagocytic NOXs, in addi-
tion to phagocytic NOX2, contributes to hepatic fibrogenesis.
Mice deficient for either NOX1 or NOX2 display significantly
less hepatic fibrosis compared with WT mice after CCl4 in-
jection or BDL (143). Experiments of hepatic fibrosis induction
in NOX1 or NOX2 bone marrow chimeric mice demonstrated
that both NOX1 and NOX2 mediate hepatic fibrosis in en-
dogenous liver cells, including HSCs, whereas NOX2 in KCs
has a lesser contribution (143). Moreover, Ang II-induced ROS
generation is more severely attenuated in NOX1-deficient
HSCs than in NOX2-deficient HSCs. The contribution of
NOX1 in hepatic fibrogenesis was corroborated by Cui et al.
(54). Cell proliferation is attenuated in HSCs isolated from
NOX1-deficient mice. NOX1-derived ROS oxidize and inac-
tivate phosphatase and tensin homologue (PTEN), which, in
turn, phosphorylates Akt and forkhead box O 4, resulting in
down-regulation of p27kip1, a cell cycle suppressor, to pro-
mote HSCs proliferation (54).
SOD1 is an enzyme that converts superoxide to H2O2.
SOD1 also interacts with Rac1 in the active NOX complex to
stimulate NOX activity. Specifically, SOD1 binds to Rac1 and
stabilizes the GTP-bound active form of Rac1 (85). Mutations
in SOD1, such as G93A and G37R, that are associated with
hereditary ALS enhance Rac1 activation and NOX-dependent
superoxide production in the spinal cord as well as in the liver
(85, 129). Hepatic ROS production and Rac1 activity are in-
creased in SOD1 G37R-mutant mice. CCl4-induced liver fi-
brosis is more pronounced in SOD1 G37R-mutant mice
compared with WT mice (7).
GKT137831 is a potent dual NOX1/NOX4 inhibitor with an
affinity similar to the irreversible, unspecific flavocytochrome
inhibitor, DPI. GKT137831 has 15-fold less potency in NOX2
and 3-fold less potency in NOX5, and it has no significant
inhibition in the NOX2-driven oxidative burst in neutrophils
(7, 112). Inhibition of NOX1 and NOX4 by GKT137831 at-
tenuates both CCl4-induced and BDL-induced ROS produc-
tion and hepatic fibrosis in WT and SOD1 G37R-mutant mice,
as well as mRNA expression of fibrogenic and NOX genes (7).
GKT137831 inhibits collagen a1(I) promoter activity and ROS
production induced by Ang II in WT and SOD1 G37R-mutant
HSCs. The specific contribution of NOX4 in hepatic fi-
brogenesis is demonstrated by the attenuation of hepatic fi-
brosis in NOX4-deficient mice compared with WT mice (97).
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Taken together, nonphagocytic NOX, including NOX1 and
NOX4 as well as phagocytic NOX2, represent fundamental
mediators in experimental hepatic fibrogenesis.
NOX-mediated redox signaling contributing
to hepatic fibrosis
Angiotensin II. The RAS plays a key role in maintaining
blood pressure homeostasis, as well as fluid and salt balance
through coordinated effects on the heart, blood vessels, and
kidneys (95). In the classic pathway of RAS, renin cleaves the
liver-derived precursor peptide angiotensinogen into the
decapeptide Ang I. Ang I is further hydrolyzed into the oc-
tapeptide Ang II by the angiotensin-converting enzyme
(ACE), which represents the main bioactive peptide of the
RAS. Angiotensinogen is the only component of the RAS that
is expressed in the normal liver. However, RAS, including
ACE and AT1R, are markedly upregulated in the fibrotic liver
(17, 146). Inhibition of Ang II synthesis and/or the blockade of
AT1R decreases hepatic inflammation and fibrosis in experi-
mental models of chronic liver injury (52, 147, 191). Con-
sistently CCl4- or BDL-induced hepatic fibrosis is reduced in
AT1R-deficient mice compared with WT mice (100, 199).
These data strongly indicate that RAS is an important medi-
ator of hepatic fibrosis. Many of the biological effects of Ang II
involve the NOX-mediated production of ROS (17, 80). Ang II
is functionally linked to NOX1, NOX2, and variably to NOX4
in the vasculature, NOX2 and NOX4 in the kidney, and NOX2
in the brain (75). p47phox - / - mice were the first used as a
genetic model to study NOX inhibition (73, 109, 114), and
p47phox - / - mice show attenuated liver injury and fibrosis
compared with WT counterparts after BDL (18).
Activated HSCs highly express AT1R, which mediates cell
proliferation, migration, and cell contraction (15). Stimulation
of HSCs with Ang II results in TGF-b and type I collagen
expression (18, 201). Ang II increases the intracellular calcium
concentration and induces production of ROS, stimulating
several key intracellular pathways, including PKC, PI3K/Akt,
and MAPKs (18). NOX mediates the intracellular pathways
induced by Ang II in HSCs (17, 18). Ang II-induced ROS
formation in HSCs is inhibited by treatment with either an
NOX inhibitor, DPI (108) or with the AT1R antagonist, lo-
sartan (52). Furthermore, Ang II induces the phosphorylation
of p47phox through AT1R in activated HSCs. In particular,
Ang II leads to an increase of intracellular ROS in HSCs iso-
lated from WT mice, but not in p47phox - / - HSCs. In addition,
Ang II induces DNA synthesis and cell migration in WT
HSCs, as well as phosphorylation of ERK and c-Jun, while
these effects are blunted in p47phox-deficient HSCs (18). Taken
together, Ang II exerts direct profibrogenic actions on HSCs
through the activation of the NOX complex and the subse-
quent production of ROS (Fig. 2).
The molecular mechanisms of NOX activation by Ang II are
complex and still incompletely understood. In VSMCs, Ang
II-stimulated ROS generation is biphasic (174). The first phase
occurs rapidly (peak at 30 s) and is dependent on PKC acti-
vation, which phosphorylates p47phox, and then phosphory-
lated p47phox translocates to the membrane where it activates
the NOX catalytic subunit NOX1 and/or NOX2. The larger
second phase of ROS generation (peak at 30 min) requires Rac
activation by upstream c-Src, EGFR transactivation, and PI3K
activation (174). Ang II may stimulate PKC-dependent NOX
activity through three different phospholipases (PLs), PLC,
PLD, and PLA2 (75). The prolonged production of NOX-
mediated ROS by Ang II requires upregulation of NOX cat-
alytic subunits and components (184). Indeed, Ang II induces
upregulation of both NOX1 and NOX4 mRNA in HSCs (7).
PDGF and leptin. PDGF, the most potent mitogen of
HSCs (153), exerts its activity, in part, through NOX (2).
PDGF-induced increase in DNA synthesis of HSC is reduced
by pre-treatment with the anti-oxidant Mn-TBAP, and also
with two different inhibitors of the NOX complex, DPI or
apocynin. PDGF-induced HSCs proliferation is suppressed by
an inhibitor of MEK or p38 MAPK, but the extent of sup-
pression is greater with the p38 MAPK inhibitor (2). The ex-
perimental model of liver fibrosis induced in mice by
parenteral DMN provides additional in vivo evidence for the
role of NOX in liver fibrosis. The use of the NADPH inhibitor
DPI or antioxidant drug Mn-TBAP reduces collagen deposi-
tion and liver fibrosis in DMN-treated mice (2). Similarly,
PDGF increases NOX activity and DNA synthesis in pancre-
atic stellate cells (93). PDGF causes hypertrophy of VSMCs by
induction of NOX1 through activation of PKCd and activating
transcription factor (ATF)-1 (67, 102). PDGF upregulates
NOX1 in VSMCs, and an adenovirus expressing antisense
NOX1 mRNA completely inhibits the early phase of super-
oxide production (115). A consensus activator protein (AP)-1
site was found at - 98/- 92 in the 5¢-flanking region of the rat
NOX1 gene (37). The NOX isoform that is responsible for
PDGF-induced mitogenic signaling in HSCs is not yet iden-
tified. NOX is also a crucial mediator of the profibrogenic
action of leptin (2, 58). Leptin-induced NOX acts downstream
of Janus kinase activation but is independent of STAT3 (58).
Thus, NOX is a core mediator of the fibrogenic signaling re-
sponse in HSCs and demonstrates its potential as a pharma-
cological target for antifibrotic therapy.
Interaction of TGF-b/Smads signaling with NOX4. TGF-
b1 induces the conversion of fibroblasts to a-SMA-expressing
myofibroblasts in multiple organs, including the heart, lung,
kidney, and liver (62, 84, 110). TGF-b1 is the strongest agonist
for HSCs activation, and it is released from KCs and recruited
macrophages with hepatic injury (14, 88). After being modi-
fied post-translationally, TGF-b1 binds to and activates
TGF-b1 receptor (TGF-bR I and II), transmembrane receptor
serine/threonine kinases (50, 175). Phosphorylation of the
receptors is accompanied by phosphorylation of Smad2 and
Smad3 that are then complexed with Smad4. Then, activated
Smad complexes enter the nucleus and initiate the transcrip-
tion of TGF-b1 target genes. Liver fibrosis is strongly reduced
in TGF-b1-deficient and Smad3-deficient mice, while over-
expression of TGF-b1 induces fibrosis in several organs, in-
cluding the liver (14, 88, 116, 166, 185).
A study using NOX4-deficient HSCs shows that TGF-b1-
mediated HSCs activation is dependent on NOX4-generating
ROS (97). NOX4 siRNA inhibits ROS production in HSCs.
Moreover, the activation of cultured HSCs is inhibited in
NOX4-deficient HSCs compared with WT HSCs (97). TGF-b1
increases the level of NOX4 mRNA and protein in an Smad3-
dependent manner, thereby increasing NOX4-derived ROS
(87, 97). NOX4 knockdown decreases HSCs activation with-
out affecting the expression of TGF-b1 and its receptor and
phosphorylation of Smad2, suggesting that NOX4-mediated
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ROS is downstream of both TGF-b1 and the Smad complex
(163). It has been reported that NOX4 acts downstream of
Smad3 in kidney and lung myofibroblasts (23, 87), but up-
stream of Smad2/3 in cardiac myofibroblasts (53). Ang II in-
duces upregulation of both NOX1 and NOX4 mRNA in HSCs
(7). Interestingly, Ang-II-induced NOX4 mRNA up-regula-
tion is suppressed in NOX1KO HSCs; however, NOX4 in-
duction by TGF-b is not suppressed in NOX1 KO HSCs. This
finding suggests that NOX1 is required for NOX4 up-regu-
lation in HSCs stimulated with Ang II, but that TGF-b induces
NOX4 independent of NOX1 in HSCs (7).
TGF-b1 induces apoptosis of hepatocytes (140). TGF-b
binds to and activates the TGF-b receptor (TGF-bR I and II),
which induces phosphorylation of Smad2 and Smad3 that
are then complexed with Smad4. Activated Smad complexes
enter the nucleus and initiate the transcription of TGF-b
target genes, including NOX4 (35). TGF-b induces NOX4
expression in rat and human hepatocytes. Knockdown
of NOX4 using siRNA attenuates NOX activity, caspase
activation, and cell death in hepatocytes, indicating that
NOX4 mediates TGF-b-induced hepatocyte apoptosis (35).
NOX4-generated H2O2 down-regulates Bcl-XL, a member of
the Bcl-2 family of pro-survival proteins, resulting in mito-
chondrial permeability transition followed by cytochrome C
release, caspase 3 activation, and apoptosis of hepatocytes
(90). In addition, NOX4-derived ROS upregulates two pro-
apoptotic genes, Bmf and Bim (31, 156). Counteracting this
effect, EGF binds to the EGFR, which, in turn, activates
MEK/ERK and PI3K/Akt, which prevents TGF-b-induced
NOX4 upregulation and hepatocyte death (34) (Fig 3.).
Furthermore, FasL or TNFa/actinomycin D-induced
apoptosis is significantly reduced in NOX4-deficient hepa-
tocytes, suggesting that NOX4 contributes to death ligand-
induced apoptosis of hepatocytes (97). Since hepatocytes
apoptosis may trigger KCs and HSCs activation by secreting
cytokines, chemokines, and microparticles, NOX4-mediated
apoptosis of hepatocytes is another mechanism contributing
to hepatic fibrosis. Taken together, NOX4 contributes to
hepatic fibrogenesis by the mechanism of inducing HSCs
activation and mediating TGF-b- or death ligand-induced
hepatocytes apoptosis (7, 97).
NOX4 generates predominantly H2O2 instead of superox-
ide (128, 173). Since H2O2 activates protein tyrosine phos-
phorylation by inhibiting phosphatases and by activating
FIG. 2. Ang II/AT1R/NOX
signaling in HSCs. Ang II
binds to AT1R, which stimu-
lates NOX-mediated ROS
generation. The molecular
mechanism of NOX activation
by Ang II on HSCs is still
poorly understood. Ang II
may stimulate PKC-dependent
NOX activity through three
different PLs such as PLC,
PLD, and PLA2. NOX-
derived ROS activate MAPK,
NF-jB, and PI3K, and in-
crease intracellular calcium
levels via L-type calcium
channel in HSCs. ROS also
inactivates PTEN, which, in
turn, further activates PI3K/




tory response in HSCs. PLs,
phospholipases; Akt, protein
kinase B; Ang II, angiotensin
II; AT1R, angiotensin type I
receptor; PKC, protein kinase
C; PTEN, phosphatase and
tensin homologue; ROS, re-
active oxygen species. To see
this illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars
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kinases, regulation of H2O2-generating NOX4 might play a
central role in mediating several TGF-b1 signaling events (11).
However, the exact mechanisms of NOX4/TGF-b-mediated
fibrogenic signaling, especially what are the targets of NOX4-
generating H2O2, are largely unknown.
Inflammation, LPS, and toll-like receptor signaling in he-
patic fibrosis. Patients with liver fibrosis have increased in-
testinal permeability, which allows entry of bacterial LPS and
CpG-containing DNAs into the liver where they stimulate
inflammatory responses through toll-like receptors (TLRs)
(171, 198). All TLRs consist of an N-terminal extracellular
domain containing leucine-rich repeats and a C-terminal
conserved cytosolic domain. While the extracellular domain
of TLRs recognizes the corresponding ligands having either
pathogen-associated molecular pattern or damage-associated
molecular pattern, the cytosolic domain mediates down-
stream signal transduction to produce interferon (IFN)-a/-b
or proinflammatory cytokines (6, 171). The inflammatory
cytokines recruit and activate KCs to release TGF-b1, which
activate HSCs.
Both quiescent and activated HSCs express the mRNAs of
multiple TLRs (190). However, HSCs respond weakly to TLR2
ligands (144, 172). TLR3 ligands are able to stimulate HSCs for
IFN-b production, but not TLR4 ligands, while macrophages
are responsive to both ligands for IFN-b production (190).
Instead, TLR4 ligands on HSCs induce NF-jB and JNK/AP-1
activation to produce proinflammatory cytokines (145). On
binding of LPS to TLR4 with the aid of CD14 and MD2, TLR4
homodimerizes and transmits signals through MyD88 and
TIRAP. Then, MyD88 recruits IL-1R-associated kinase
(IRAK)-1/-4, and activates NF-jB through the TRAF6/
TAK1/TAB2 complex (6, 171). Activated NF-jB enters the
nucleus and drives the transcription of various chemokines
(MCP-1, MIP-1a, RANTES, and IL-8) and adhesion molecules
(ICAM-1 and VCAM-1). Then, those molecules facilitate the
recruitment of KCs and circulating macrophages to the site of
HSCs, where KCs and recruited macrophages release TGF-b1
FIG. 3. TGF-b mediates
apoptosis of hepatocytes via
NOX4 upregulation. After
various kinds of liver injury,
including alcohol, HCV, and
toxic bile acids, ROS is pro-
duced via NOXs in hepato-
cytes, some hepatocytes
undergo apoptosis/necrosis,
and KCs get activated, releas-
ing proinflammatory and pro-
fibrogenic cytokines such as
TGF-b. TGF-b binds to and ac-
tivates TGF-b receptor (TGF-bR
I and II), which is accompanied
by phosphorylation of Smad2
and Smad3 that are then com-
plexed with Smad4. Then, acti-
vated Smad complexes enter
the nucleus and initiate the
transcription of TGF-b target
genes, including NOX4. NOX4-
generated H2O2 down-regu-
lates Bcl-XL, a Bcl-2 family of
pro-survival protein, resulting
in mitochondrial permeability
transition in mitochondria fol-
lowed by cytochrome C release,
caspase 3 activation, and apo-
ptosis of hepatocytes. How-
ever, EGF binds to EGF
receptor, which, in turn, acti-
vates MEK/ERK and PI3K/
Akt and blocks TGF-b-induced
NOX4 upregulation and he-
patocytes cell death. EGF, epi-
dermal growth factor; ERK,
extracellular signal-regulated
kinase; H2O2, hydrogen perox-
ide; HCV, hepatitis C virus. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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to activate HSCs (6, 198). In fact, antibiotic treatment to reduce
the gut microflora attenuates liver fibrosis, indicating the es-
sential role of bacterial products in hepatic fibrogenesis, and
TLR4-mutant mice and MyD88-deficient mice are resistant to
fibrosis (172).
HSCs containing a collagen promoter-driven GFP reporter
(Col1-GFP) show weak reporter activity on TGF-b1 stimula-
tion, but much better reporter activity on pretreatment with
LPS, suggesting that LPS-TLR4 signaling primes HSCs for
TGF-b1 signaling (172). In addition, coculture studies of
TLR4-mutant KCs with Col1-GFP containing HSCs show that
LPS stimulation does not enhance TGF-b1-mediated reporter
activity, suggesting that KCs are not responsible for LPS-
TLR4-mediated HSCs activation. Indeed, two TLR4 SNP
mutants, T399I and D299G, reduce not only NF-jB activity
and chemokine production, but also HSCs activation (82).
Gene expression analysis identified bone morphogenetic
protein and activin membrane-bound inhibitor (Bambi) as a
key factor for LPS-TLR4-mediated enhancement of HSCs ac-
tivation by TGF-b1 (172). HSCs, but not KCs and hepatocytes,
express high levels of Bambi that binds TGF-b1 receptor and
inhibits Smad3 phosphorylation on TGF-b1 stimuli (142, 172,
197). LPS-TLR4 in HSCs activates NF-jB in an MyD88-TIRAP-
dependent manner, activates NF-jB, and down-regulates
Bambi, thereby rendering HSCs ready for TGF-b1-mediated
activation (Fig. 4) (172).
Little work has been reported on the role that NOX or ROS
might play in LPS-TLR4 mediated inflammatory or fibrogenic
signaling in HSCs. LPS induces the expression of NOX1
through TLR4 in macrophages, suggesting that the interaction
between LPS/TLR4 signaling and NOX1 might modulate fi-
brogenic response in the liver (104). In neutrophils, antioxi-
dant treatment reduces LPS-stimulated nuclear localization of
NF-jB (10). In macrophages, NOX inhibitors (DPI and apoc-
ynin) or siRNA against p22phox greatly diminish LPS-TLR4-
mediated X-box-binding protein 1 splicing, a marker of ER
stress, suggesting that ROS plays an important role in LPS-
TLR4 signaling (127). Moreover, yeast-two hybrid assay and
GST-pull down assay in HEK 293 cells demonstrates that the
C-terminal domain of NOX4 interacts with the C-terminal
FIG. 4. Interactions be-
tween TGFb-NOX4 and
LPS-TLR4-mediated profi-
brogenic signaling in HSCs.
TGF-b released from injured
hepatocytes and activated
KCs binds to TGF-b receptor,
which, in turn, upregulates
NOX4 in an Smad2/3-
dependent manner in HSCs.
NOX4-generated H2O2 acti-
vates collagen a1 promoter to
produce type I collagen in HSCs
promoting hepatic fibrosis. Gut-
derived LPS binds TLR4 and
activates NF-jB via MyD88/
TIRAP/IRAKs/TRAF6 path-
way, which, in turn, sup-
presses BAMBI, a TGF-b
inhibitor, in HSCs. LPS/
TLR4/MyD88/NF-jB signal-
ing further propagates TGF-b/
NOX4-mediated profibrogenic
redox signaling via down-
regulation of BAMBI in HSCs.
TLR, toll-like receptor; IRAK,
IL-1R-associated kinase. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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cytosolic domain of TLR4 (149). In human aortic ECs, over-
expression of the C-terminal region of NOX4 inhibits LPS-
mediated NF-jB activation, via reduced ROS production
(148). Moreover, siRNA of NOX4 decreases adhesion mole-
cule (ICAM-1) and chemokines (IL-8 and MCP-1) by LPS
stimulation, suggesting that LPS-TLR4 signaling induces NF-
jB activation and inflammatory responses through NOX4-
derived ROS in human aortic ECs (148). Interestingly, mouse
renal tubule epithelial cells express a splicing variant of NOX4
(28 kDa NOX4) more than full-length 65 kDa NOX4, and the
28-kDa NOX4 interacts with TLR4 in co-immunoprecipitation
(22). Therefore, future studies are needed to determine the
role of NOX4-derived ROS in mediating the LPS-TLR4-NF-jB
cascade in HSCs activation, perhaps through a direct inter-
action between NOX4 and TLR4.
Therapeutic strategies and future direction
of NOX-mediated hepatic fibrosis
Based on the knowledge of the pathogenic role of ROS in
hepatic fibrogenesis, clinical trials of antifibrotic therapy
targeting oxidative stress using antioxidants have been at-
tempted in several kinds of chronic liver disease. However,
treatment using agents with nonspecific antioxidant actions
such as vitamin E, vitamin C, polyenyl phosphatidyl choline,
or UDCA failed to demonstrate antifibrotic efficacy in pa-
tients with various kinds of chronic liver disease, including
alcoholic hepatitis (121), NASH (122, 165), and chronic
hepatitis C (202). Moreover, high doses of vitamin E sup-
plementation ( ‡ 400 IU/day) may increase all-cause mor-
tality (130). Perhaps more potent and specific inhibitors of
oxidative stress may be required for the development of
antifibrotic agents.
The multiple lines of evidence demonstrating the critical
role of NOX in hepatic fibrogenesis provide a strong rationale
for the use of pharmacological inhibitors of NOX to treat pa-
tients with chronic liver disease. Ang II blocking agents are
the first such drugs that have been assessed by several in-
vestigators. Antifibrotic effects of angiotensin type 1 receptor
(AT1-R) blocker (ARB) are reported in several retrospective or
small pilot studies in patients with chronic hepatitis C (51, 160,
178) and NASH (200), The effects of losartan, an ARB, on liver
fibrosis in patients with chronic hepatitis C were prospec-
tively investigated (49). Baseline biopsies showed that the
degree of fibrosis was F2 in seven patients (50%), F3 in four
patients (29%), and F4 in three patients (21%). After 18 months
of oral losartan 50 mg/day treatment, the degree of fibrosis
decreased in seven patients (50%), remained unchanged in
three patients (21%), and progressed in four patients (29%).
Furthermore, losartan treatment was associated with a sig-
nificant decrease in the expression of several fibrogenic genes,
including procollagen a1(I) and a1(IV), urokinase type plas-
minogen activator, metalloproteinase type 2, and NOX genes,
including NOXO1, NOXA1, and Rac1 (49). The demonstra-
tion that AT1R blockade is associated with a decrease in
procollagen a1(I) suggests that losartan inhibits collagen
synthesis in patients with chronic hepatitis C. Since prolonged
hepatic necroinflammation results in fibrosis, the anti-
inflammatory effect of losartan may also contribute to the
reduction of hepatic fibrosis. Recently, a randomized con-
trolled study by Kim et al. reported that candesartan, an ARB,
decreases hepatic fibrosis as well as hepatic expression of
NOX components such as p22phox and Rac1 in patients with
alcoholic liver disease (105).
In contrast, long-term administration of angiotensin-
converting enzyme inhibitor (ACEi) or ARB did not retard the
progression of hepatic fibrosis in patients with chronic hepa-
titis C who were enrolled in the HALT-C cohort (1). Specifi-
cally, fibrosis progression occurred in 33.3% of the ACEi/ARB
group, 32.5% of the other antihypertensive medications
group, and in 25.7% of subjects taking no antihypertensive
medications among the HALT-C cohort. Cholongitas et al.
investigated the effect of ARB use in a cohort of 102 consec-
utive hypertensive patients with recurrent HCV after liver
transplantation. Administration of an ARB was associated
with less progression in inflammation but not in fibrosis (45).
These conflicting results suggest the possibility that ARB’s
antifibrotic efficacy may vary according to the etiology of the
chronic liver disease or that alone are insufficient to block the
multiple fibrogenic pathways. The extent of hepatic fibrosis
may be an important factor that affects anti-fibrotic effects of
ARB. ARB may exert the maximal anti-fibrogenic effects early
in the fibrogenic process, and this effect may diminish at a
later stage of fibrosis (1, 181). Further well-designed, large-
scale clinical studies are required to determine the antifibrotic
efficacy of ARB in the specific setting of chronic liver disease.
A clinical study is underway to examine the efficacy of irbe-
sartan on the progression of liver fibrosis in adult patients
with chronic hepatitis C (ClinicalTrials.gov NCT00265642).
The development of novel pharmacological NOX inhibitors
is being assessed as potential anti-fibrotic therapeutics for
hepatic fibrosis. Detailed information of these NOX inhibitors
has been provided in comprehensive review articles (46, 65,
96). Recently, a small molecule NOX1/NOX4 dual inhibitor
was developed by GenKyoTex (Geneva, Switzerland) (112).
As previously mentioned, the inhibition of both NOX1 and
NOX4 by GKT137831 attenuates CCl4- or BDL-induced ROS
production and hepatic fibrosis in mice (7, 97). GKT137831
inhibits collagen a1(I) promoter activity, and it suppresses
TGF-b, aSMA, and ROS production in HSCs. NOX4 also
mediates lung myofibroblasts activation and fibrogenic re-
sponses in lung (87). GKT137831 attenuates hypoxia-induced
H2O2 release, proliferation, and TGF-b1 expression in human
pulmonary artery endothelial or smooth muscle cells (79). In
2010, GKT137831 was granted orphan drug status for the
treatment of idiopathic pulmonary fibrosis by the European
Commission (86). In phase I clinical study, GKT137831 was
found to be safe and well tolerated when administered orally
to a total of 72 healthy adult men, at single doses of approx-
imately 1800 mg OD, and at multiple doses of approximately
900 mg OD for 10 days. The results of animal study and phase
I clinical study warrant a clinical trial of GKT137831 to in-
vestigate antifibrotic efficacy in the treatment of hepatic
fibrosis.
When considering NOX inhibition as a therapeutic strategy
for hepatic fibrosis, the collateral inhibition of normal physi-
ological function of NOX should be also considered. For ex-
ample, the protective role of NOX4 in vasculature from
ischemic or inflammatory injury was reported (168). Loss of
NOX4 results in the reduction of endothelial nitric oxide
synthase expression, nitric oxide production, and heme
oxygenase-1 expression, which was associated with apoptosis
and inflammatory activation in vasculature (168). Since the
liver comprises multiple cell types that express multiple NOX
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isoforms, inhibition of specific NOX isoforms may disturb the
normal physiological role. A better understanding of the
components and functions of specific NOX isoforms in spe-
cific cell types and interactions of NOX signaling between cell
types in the liver may answer these unresolved questions.
Conclusions
NOX-generated ROS is implicated in the pathogenesis of
various kinds of chronic liver disease. A growing body of
literature indicates that the excessive amount of ROS gener-
ated by NOX plays a pivotal role in hepatic fibrogenesis.
Importantly, nonphagocytic NOXs, including NOX1 and
NOX4 as well as phagocytic NOX2 in HSCs, mediate hepatic
fibrosis. Of note, NOX4-mediated ROS generation is related
to TGF-b/Smads signaling, critical profibrogenic signaling
pathways in the liver. Various NOX isoforms expressed in cell
types comprising the liver such as KCs, ECs, hepatocytes, and
infiltrating leukocytes also seem to be involved in hepatic fi-
brogenesis. However, identification and regulation of the
NOX isoforms in specific cell types in the liver are still largely
unknown. Targeting specific NOX isoforms such as NOX1
and/or NOX4 may be promising to treat hepatic fibrosis,
while escaping the collateral suppression of host defence
caused by NOX2 inhibition. A better understanding about
NOX-mediated fibrogenic signaling may enable the devel-
opment of novel anti-fibrotic therapy using NOX inhibition
strategy.
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ACE¼ angiotensin converting enzyme
ACEi¼ angiotensin-converting enzyme inhibitor
Akt¼protein kinase B
ALS¼ amyotrophic lateral sclerosis
Ang II¼ angiotensin II
AP¼ activator protein
ARB¼ angiotensin receptor blocker
AT1R¼ angiotensin type I receptor
ATF¼ activating transcription factor
BDL¼ bile duct ligation
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PTEN¼phosphatase and tensin homologue
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TLR¼ toll-like receptor
VSMCs¼vascular smooth muscle cells
WT¼wild-type
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